Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
Prohibited at all times under the open 2026 anti-estrogen class S4.2; Specified. Named explicitly in the future 2027 List. [1] [2] [3]
S4.2 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulation
Imlunestrant is an oral estrogen-receptor antagonist. The September 2026 US Inluriyo label covers adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine-therapy progression, either alone or with abemaciclib. [4]
- This is the checked US label, not a worldwide authorization or availability inventory.
Selected health warnings
Fetal harm and CYP3A interactions are important label issues. Reported reactions and laboratory changes differ between monotherapy and combination therapy; the latter must not be presented as the risk profile of imlunestrant alone. Medical authorization does not remove anti-doping restrictions. [4]
- The full label and clinician assessment remain necessary; listed risks are not exhaustive.
What remains uncertain
- No product-specific supplement-contamination pathway was established in this review; a medicine label does not establish contamination prevalence.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- WADA 2027 Prohibited List November revision ↗Accessed 2026-11-10 · Relevant official full-text sections opened · FUTURE 2027 SOURCE
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- UKAD 2027 Prohibited List: Summary of Changes ↗Accessed 2026-11-10 · Relevant document text opened · FUTURE 2027 SOURCE
Relevant cited sections
- Inluriyo imlunestrant ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.